GNTA: Bathi resik saben saham (EPS TTM) Genenta Science SpA

Genenta Science S.p.A. bases its development on bioethics and environmental safety when creating cellular therapies. The change in rolling net income per share demonstrates capital dynamics, where the current value of the indicator is -0.37. High R&D expenditures and patents for viral vectors create an insurmountable barrier to entry, protecting the company's developments from new competitors in oncology.

GNTA (Genenta Science S.p.A.) riwayat Bathi resik saben siji saham sajrone rolas wulan pungkasan saka 04.07.2022 nganti 04.11.2026

genenta.com - rincian analitis lan metrik utama (GNTA)

- rega saham lan prakiraan rega para ahli:

Kutipan saham Genenta Science|GNTA - Konsensus nilai wajar

- informasi kapitalisasi pasar:

Kapitalisasi pasar Genenta Science S.p.A.|GNTA - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Genenta Science|GNTA - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku genenta.com|GNTA - Aset Agregat Perusahaan

- data utang lan likuiditas:

- indikator pendapatan resik lan kelipatan nilai:

GNTA - Bathi perusahaan|Proyeksi bathi mangsa ngarep Genenta Science S.p.A.|GNTA - Kapitalisasi marang bathi|Prakiraan rega marang bathi Genenta Science|GNTA - Koefisien bali modal nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Genenta Science S.p.A.|GNTA - Bathi perusahaan sadurunge pajak, bunga, lan amortisasi|Bathi resik saben saham (EPS TTM) Genenta Science|GNTA - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan genenta.com|GNTA - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Genenta Science S.p.A.

- data pendapatan lan penerimaan dodolan:

GNTA - Pendapatan dodolan perusahaan|Prakiraan volume dodolan Genenta Science S.p.A.|GNTA - Multiplikator P/S|Rasio rega marang prakiraan pendapatan Genenta Science SpA

Analisis umum perusahaan:Genenta Science SpA (GNTA)

Genenta Science S.p.A. is investing in innovative gene therapy delivery to combat glioblastoma. Net earnings per share over the last four quarters reflect the final financial result distributed across the total volume of the issue. Growth in this indicator confirms the effectiveness of cost management while scaling clinical trials. A declining trend signals expanding operating expenses. The dynamics of this metric directly determine the investment attractiveness of the market capitalization.

Analisis perusahaan pesaing